Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Promotion Not Enough For Fed Intervention – Patton Boggs Lawyer

This article was originally published in The Pink Sheet Daily

Executive Summary

Justice Department is unlikely to investigate off-label drug claims unless a firm is also offering kickbacks or bilking Medicare or Medicaid, Laura Laemmle asserts, discussing recent case against drug firm Serono.

You may also be interested in...

Angiotech Pharma Looks To Become Less Reliant On Device Partners

Dependence on Boston Scientific's Taxus royaltieis will fall significantly once Angiotech offers AMI's oncology, aesthetic, wound closure and ophthalmology devices.

Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis

Allergan may be forced to divest more than Inamed's development-stage botulinum toxin type A product, Reloxin.

Medicare Costs Will Likely Rise With Improved Cardiac Therapies – RAND

Medical advances for devices, vaccines, telomerase inhibitors and disease prevention programs will lead to more rapid cost increases than the rising incidence of chronic disease, according to RAND Corporation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts